Navigation Links
Landmark study of more than 27,000 women shows favorable results of Roche's CINtec PLUS cytology test
Date:11/4/2013

TUCSON, Ariz., Nov. 4, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, is pleased to announce the positive findings of the Primary ASC-US LSIL Marker Study (PALMS) that have been published in The Journal of the National Cancer Institute.1 The pan-European study, including more than 27,000 women from five European countries,  was performed to estimate the diagnostic performance of the CINtec® PLUS* cytology test in screening for cervical precancers compared to more traditional screening methods like Pap cytology. The study assessed whether the test, which uses two biomarkers, p16 and Ki-67, that are indicative of oncogenic (cancer-causing) human papillomavirus (HPV) infections, provides both high sensitivity and specificity for high-grade precancerous cervical lesions. The results showed that when compared to Pap cytology testing, the CINtec PLUS cytology test was more effective than Pap cytology in detecting precancerous lesions.  Pap cytology had a sensitivity of 67.5% while the CINtec PLUS test had a sensitivity of 86.7%.

(Photo: http://photos.prnewswire.com/prnh/20131104/LA09354 )

"The results of PALMS confirms data from previous studies which have shown that incorporating the CINtec PLUS test in cervical cancer screening programs can provide real benefit to both clinicians and their patients," says Dr. Christine Bergeron, Laboratoire Cerba, Cergy, Paris, France, PALMS study investigator and publication co-author.  "In young women, where HPV infection rates may be high, the CINtec PLUS test could be very useful to identify those women with clinically significant precancers who may be missed by the lower sensitivity Pap test.  In older women, combining the CINtec PLUS test with HPV DNA testing would make a lot of sense."

More than 500,000 new cases of cervical cancer are diagnosed each year worldwide.2 Disappointingly, the average five-year survival rate of patients is only around 50%.2 HPV infections are common and cause virtually all cervical cancer.2  However, only those women with persistent HPV infections and who have developed high-grade precancerous cervical disease should be treated. The CINtec PLUS cytology test was developed to help identify those HPV infections that may lead to cancer and distinguish them from those that will not.

The authors (Safaeian and Sherman) of an editorial published along with the PALMS study results write that dual biomarker screening could have a role in primary screening, especially in younger women. They also conclude that the dual assay could serve as a triage for positive HPV tests and could dramatically decrease patient referrals to colposcopy and other invasive and costly procedures unnecessarily.

"The results demonstrated in the PALMS trial reinforces the medical value Roche brings to cervical cancer screening.  We are committed to improving patient outcomes by providing differentiated diagnostic tools for doctors and laboratories," says Mara G. Aspinall, President, Ventana Medical Systems, Inc.  "We are pleased to announce that a fully automated version of the CINtec® PLUS cytology test will be launching later this year and will join the cobas® HPV test and the CINtec® Histology test to complete our portfolio of cervical cancer screening products."

*The CINtec® PLUS cytology test is not available in all geographies and/or may not be approved for all uses discussed in this press release.

1JNCI – The Journal of the National Cancer Institute (Ikenberg et al. Screening for Cervical Cancer Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS Study. J Natl Cancer Inst. 2013;105(20):1550-1557); PUBMED: www.ncbi.nlm.nih.gov/pubmed/24096620.

2 World Health Organization Fact Sheet 380, September 2013: http://www.who.int/mediacentre/factsheets/fs380/en/

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. VENTANA, the VENTANA logo and cobas are trademarks of Roche. Other trademarks are the property of their respective owners.

Visit www.ventana.com to learn more.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: Jacquie Bucher


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Survey of Participants from Landmark GRACE Trial Provides Patients Perspectives from an HIV Clinical Study
2. Behind the Landmark Weeks Case
3. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
4. Fuse Science Announces Landmark Licensing Agreement with Industry Leader Macular Health
5. SurgiCount Medical Achieves Landmark Product Usage And Customer Milestones
6. PRA Participates in Landmark Alzheimers Prevention Clinical Trial
7. President Obama Signs Landmark Accessible Prescription Drug Label Bill
8. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
9. Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
10. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
11. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... SOUTHLAKE, Texas , May 25, 2016 /PRNewswire/ ... today the issuance to it by the US ...  9,218,608. The company,s technology includes proprietary processes for ... claims for health and wellness programs, HIPAA compliance ... "Our ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)...  Diana Russell suffers from a form of rheumatoid ... out.  This disease has put her in a wheelchair, ... grandchildren to leave her home.  Because of the size ... the wheelchair.  So if there is a family function, ... left to wait for the bus. Photo ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can ... drop a preset onto their media," said Christina Austin - CEO of Pixel Film ... can quickly and easily add stylish color grades to their footage. A LUT is ...
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third ... is not surprising that bariatric surgery has received increased attention in recent years, as ... course, when it comes to weight loss, most people are familiar with the basic ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... campaign returns for a third time to shed lights on the variety of topics ... and inspirational stories, “Nurse Appreciation” tackles why this career has gone from being in ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to ... who are unaware of the plight of aphasia. In collaboration with the American ... Awareness” campaign. , The link between stroke and aphasia is relatively unknown, but ...
(Date:5/27/2016)... ... 27, 2016 , ... Each year Standard Process Inc. ... is this year’s Life University winner of a $2,500 scholarship from ... Leadership Awards ceremony. , Outerbridge is approaching her last quarter at Life University ...
Breaking Medicine News(10 mins):